Exploiting the unique features of Zika and Dengue proteases for inhibitor design
Language English Country France Media print-electronic
Document type Journal Article, Review
PubMed
31077760
DOI
10.1016/j.biochi.2019.05.004
PII: S0300-9084(19)30143-9
Knihovny.cz E-resources
- Keywords
- Active-site inhibitors, Allosteric inhibitors, Aptamers, Dengue protease, Precursor, Zika protease,
- MeSH
- Allosteric Site MeSH
- Antiviral Agents chemistry pharmacology MeSH
- Dengue drug therapy virology MeSH
- Zika Virus Infection drug therapy virology MeSH
- Protease Inhibitors chemistry pharmacology MeSH
- Catalytic Domain MeSH
- Kinetics MeSH
- Protein Conformation MeSH
- Humans MeSH
- Peptide Hydrolases chemistry metabolism MeSH
- Drug Design * MeSH
- Serine Endopeptidases chemistry metabolism MeSH
- Viral Proteins antagonists & inhibitors chemistry metabolism MeSH
- Dengue Virus drug effects enzymology MeSH
- Zika Virus drug effects enzymology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Antiviral Agents MeSH
- Protease Inhibitors MeSH
- NS3 protease, dengue virus MeSH Browser
- NS3 protein, zika virus MeSH Browser
- Peptide Hydrolases MeSH
- Serine Endopeptidases MeSH
- Viral Proteins MeSH
Zika and Dengue viruses have attracted substantial attention from researchers in light of recent outbreaks of Dengue fever and increases in cases of congenital microcephaly in areas with Zika incidence. This review summarizes the current state of knowledge about Zika and Dengue proteases. These enzymes have several interesting features: 1) NS3 serine protease requires the activating co-factor NS2B, which is anchored in the membrane of the endoplasmic reticulum; 2) NS2B displays extensive conformational dynamics; 3) NS3 is a multidomain protein with proteolytic, NTPase, RNA 5' triphosphatase and helicase activity and has many protein-protein interaction partners; 4) NS3 is autoproteolytically released from its precursor. Attempts to design tight-binding and specific active-site inhibitors are complicated by the facts that the substrate pocket of the NS2B-NS3 protease is flat and the active-site ligands are charged. The ionic character of potential active-site inhibitors negatively influences their cell permeability. Possibilities to block cis-autoprocessing of the protease precursor have recently been considered. Additionally, potential allosteric sites on NS2B-NS3 proteases have been identified and allosteric compounds have been designed to impair substrate binding and/or block the NS2B-NS3 interaction. Such compounds could be specific to viral proteases, without off-target effects on host serine proteases, and could have favorable pharmacokinetic profiles. This review discusses various groups of inhibitors of these proteases according to their mechanisms of action and chemical structures.
References provided by Crossref.org
The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery
Viral proteases as therapeutic targets
